The MAPK/ERK signaling pathway is another vital target for inhibitors. This pathway is associated with controling cell growth, survival, and distinction. Inhibitors targeting MAPK/ERK are employed in cancer cells therapies to stop unrestrained cell expansion and lump development. JAK/STAT signaling inhibitors modulate immune responses and are used